Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment

Patients with hypercholesterolemia often have coronary microvascular dysfunction (CMD). Viral infections, such as the SARS-CoV-2 infection, may also result in CMD. Three non-randomized studies have shown significant beneficial effects of statins on CMD in non-infected patients. Similarly, in SARS-CoV-2 - infected patients one beneficial mechanism of action of statins may be the amelioration of endothelial dysfunction, which is a major driver of CMD. Apart from statins, lipoprotein apheresis and PCSK9 inhibitors can also improve or even reverse CMD. The potential reversal of CMD by using effective cholesterol-lowering medications during and after COVID-19 infection, especially in hypercholesterolemic COVID-19 patients, is important.

Automated summary

Patients with hypercholesterolemia often have coronary microvascular dysfunction (CMD), which can also be caused by viral infections like SARS-CoV-2. Several studies have shown that statins can improve CMD in non-infected patients. In SARS-CoV-2-infected patients, statins may also ameliorate endothelial dysfunction, a major driver of CMD. Other cholesterol-lowering medications like lipoprotein apheresis and PCSK9 inhibitors can also improve or reverse CMD. The potential reversal of CMD through effective cholesterol-lowering medications during and after COVID-19 infection, especially in hypercholesterolemic patients, is significant.